人卵母细胞体外成熟研究进展:现状与展望

IF 3.4 Q2 REPRODUCTIVE BIOLOGY
Meiju Liu, Jie Cui, Hsun-Ming Chang, Jing Liu, Peter C K Leung
{"title":"人卵母细胞体外成熟研究进展:现状与展望","authors":"Meiju Liu, Jie Cui, Hsun-Ming Chang, Jing Liu, Peter C K Leung","doi":"10.1530/RAF-25-0092","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Oocyte in vitro maturation (IVM) is an evolving component of assisted reproductive technology (ART) that offers a less invasive and cost-effective alternative to conventional controlled ovarian stimulation. It is particularly beneficial for patients at risk of ovarian hyperstimulation syndrome (OHSS), those with polycystic ovary syndrome (PCOS), and individuals requiring urgent fertility preservation. Despite these advantages, clinical uptake has remained limited owing to concerns about the developmental competence and quality of IVM-derived oocytes. To address this, we conducted a comprehensive literature search of PubMed, Embase, and Web of Science for articles published between January 2000 and June 2025, using combinations of keywords related to IVM, oocyte maturation, culture protocols, oocyte quality, and clinical outcomes. Recent progress in the field has led to the development of biphasic culture systems, pre-IVM priming strategies, and the incorporation of regulatory factors such as C-type natriuretic peptide (CNP) and oocyte-secreted factors (OSFs), all of which have contributed to improved oocyte maturation and embryo development. Nonetheless, variability in outcomes persists due to differences in patient selection, stimulation protocols, and laboratory practice. Continued optimisation of IVM culture systems and a deeper understanding of oocyte maturation mechanisms will be essential for enhancing clinical efficacy. Future research should prioritise standardisation, patient-tailored protocols, and systematic long-term outcome data to support wider adoption of IVM. This review provides a comprehensive overview of recent advances and ongoing challenges in human oocyte IVM, offering perspectives on future directions for clinical translation and improved ART outcomes.</p><p><strong>Lay summary: </strong>In vitro maturation (IVM) is a fertility treatment that allows immature eggs to mature in the laboratory rather than within the body. This approach can be safer, simpler, and more affordable than traditional IVF, especially for women with polycystic ovary syndrome (PCOS), those at risk of ovarian hyperstimulation, or those who need to preserve their fertility quickly, such as cancer patients. Although IVM holds great promise, it is not yet widely used because its success rates are not as high as those of conventional methods. This review looks at the latest scientific progress to improve IVM, including better laboratory techniques, the use of natural hormones and growth factors, and new ways to support egg development outside the body. These advancements have helped improve the quality of eggs and embryos, but challenges remain. Differences in patient types, medications used, and lab practices can affect how well IVM works. More research is needed to make IVM more consistent and effective so it can become a routine fertility option for a broader population.</p>","PeriodicalId":101312,"journal":{"name":"Reproduction & fertility","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in Human Oocyte In Vitro Maturation: Current Status and Future Perspectives --- a Narrative Review.\",\"authors\":\"Meiju Liu, Jie Cui, Hsun-Ming Chang, Jing Liu, Peter C K Leung\",\"doi\":\"10.1530/RAF-25-0092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Oocyte in vitro maturation (IVM) is an evolving component of assisted reproductive technology (ART) that offers a less invasive and cost-effective alternative to conventional controlled ovarian stimulation. It is particularly beneficial for patients at risk of ovarian hyperstimulation syndrome (OHSS), those with polycystic ovary syndrome (PCOS), and individuals requiring urgent fertility preservation. Despite these advantages, clinical uptake has remained limited owing to concerns about the developmental competence and quality of IVM-derived oocytes. To address this, we conducted a comprehensive literature search of PubMed, Embase, and Web of Science for articles published between January 2000 and June 2025, using combinations of keywords related to IVM, oocyte maturation, culture protocols, oocyte quality, and clinical outcomes. Recent progress in the field has led to the development of biphasic culture systems, pre-IVM priming strategies, and the incorporation of regulatory factors such as C-type natriuretic peptide (CNP) and oocyte-secreted factors (OSFs), all of which have contributed to improved oocyte maturation and embryo development. Nonetheless, variability in outcomes persists due to differences in patient selection, stimulation protocols, and laboratory practice. Continued optimisation of IVM culture systems and a deeper understanding of oocyte maturation mechanisms will be essential for enhancing clinical efficacy. Future research should prioritise standardisation, patient-tailored protocols, and systematic long-term outcome data to support wider adoption of IVM. This review provides a comprehensive overview of recent advances and ongoing challenges in human oocyte IVM, offering perspectives on future directions for clinical translation and improved ART outcomes.</p><p><strong>Lay summary: </strong>In vitro maturation (IVM) is a fertility treatment that allows immature eggs to mature in the laboratory rather than within the body. This approach can be safer, simpler, and more affordable than traditional IVF, especially for women with polycystic ovary syndrome (PCOS), those at risk of ovarian hyperstimulation, or those who need to preserve their fertility quickly, such as cancer patients. Although IVM holds great promise, it is not yet widely used because its success rates are not as high as those of conventional methods. This review looks at the latest scientific progress to improve IVM, including better laboratory techniques, the use of natural hormones and growth factors, and new ways to support egg development outside the body. These advancements have helped improve the quality of eggs and embryos, but challenges remain. Differences in patient types, medications used, and lab practices can affect how well IVM works. More research is needed to make IVM more consistent and effective so it can become a routine fertility option for a broader population.</p>\",\"PeriodicalId\":101312,\"journal\":{\"name\":\"Reproduction & fertility\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reproduction & fertility\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1530/RAF-25-0092\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"REPRODUCTIVE BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproduction & fertility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/RAF-25-0092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

卵母细胞体外成熟(IVM)是辅助生殖技术(ART)的一个不断发展的组成部分,它提供了一种侵入性更小、成本效益更高的替代方法。对于有卵巢过度刺激综合征(OHSS)风险的患者、多囊卵巢综合征(PCOS)患者和需要紧急保留生育能力的个体尤其有益。尽管有这些优势,但由于对体外受精衍生卵母细胞的发育能力和质量的担忧,临床摄取仍然有限。为了解决这个问题,我们对PubMed、Embase和Web of Science进行了全面的文献检索,检索2000年1月至2025年6月期间发表的文章,使用与IVM、卵母细胞成熟、培养方案、卵母细胞质量和临床结果相关的关键词组合。该领域的最新进展导致了双相培养系统的发展,ivm前启动策略,以及c型利钠肽(CNP)和卵母细胞分泌因子(OSFs)等调节因子的结合,所有这些都有助于改善卵母细胞成熟和胚胎发育。尽管如此,由于患者选择、刺激方案和实验室实践的差异,结果的可变性仍然存在。继续优化IVM培养系统和更深入地了解卵母细胞成熟机制对于提高临床疗效至关重要。未来的研究应优先考虑标准化、患者定制方案和系统的长期结果数据,以支持IVM的更广泛采用。这篇综述全面概述了人类卵母细胞体外受精的最新进展和面临的挑战,并对临床转化和改善ART结果的未来方向提出了展望。摘要:体外成熟(IVM)是一种生育治疗方法,它允许未成熟的卵子在实验室而不是在体内成熟。这种方法比传统的体外受精更安全、更简单、更实惠,特别是对于患有多囊卵巢综合征(PCOS)的女性、有卵巢过度刺激风险的女性,或者需要快速保持生育能力的女性,比如癌症患者。尽管IVM具有很大的前景,但由于其成功率不如传统方法高,因此尚未得到广泛应用。这篇综述着眼于改善体外受精的最新科学进展,包括更好的实验室技术,天然激素和生长因子的使用,以及支持卵子体外发育的新方法。这些进步有助于提高卵子和胚胎的质量,但挑战依然存在。患者类型、使用的药物和实验室实践的差异会影响IVM的效果。需要进行更多的研究以使体外受精更加一致和有效,从而使其成为更广泛人群的常规生育选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Advances in Human Oocyte In Vitro Maturation: Current Status and Future Perspectives --- a Narrative Review.

Abstract: Oocyte in vitro maturation (IVM) is an evolving component of assisted reproductive technology (ART) that offers a less invasive and cost-effective alternative to conventional controlled ovarian stimulation. It is particularly beneficial for patients at risk of ovarian hyperstimulation syndrome (OHSS), those with polycystic ovary syndrome (PCOS), and individuals requiring urgent fertility preservation. Despite these advantages, clinical uptake has remained limited owing to concerns about the developmental competence and quality of IVM-derived oocytes. To address this, we conducted a comprehensive literature search of PubMed, Embase, and Web of Science for articles published between January 2000 and June 2025, using combinations of keywords related to IVM, oocyte maturation, culture protocols, oocyte quality, and clinical outcomes. Recent progress in the field has led to the development of biphasic culture systems, pre-IVM priming strategies, and the incorporation of regulatory factors such as C-type natriuretic peptide (CNP) and oocyte-secreted factors (OSFs), all of which have contributed to improved oocyte maturation and embryo development. Nonetheless, variability in outcomes persists due to differences in patient selection, stimulation protocols, and laboratory practice. Continued optimisation of IVM culture systems and a deeper understanding of oocyte maturation mechanisms will be essential for enhancing clinical efficacy. Future research should prioritise standardisation, patient-tailored protocols, and systematic long-term outcome data to support wider adoption of IVM. This review provides a comprehensive overview of recent advances and ongoing challenges in human oocyte IVM, offering perspectives on future directions for clinical translation and improved ART outcomes.

Lay summary: In vitro maturation (IVM) is a fertility treatment that allows immature eggs to mature in the laboratory rather than within the body. This approach can be safer, simpler, and more affordable than traditional IVF, especially for women with polycystic ovary syndrome (PCOS), those at risk of ovarian hyperstimulation, or those who need to preserve their fertility quickly, such as cancer patients. Although IVM holds great promise, it is not yet widely used because its success rates are not as high as those of conventional methods. This review looks at the latest scientific progress to improve IVM, including better laboratory techniques, the use of natural hormones and growth factors, and new ways to support egg development outside the body. These advancements have helped improve the quality of eggs and embryos, but challenges remain. Differences in patient types, medications used, and lab practices can affect how well IVM works. More research is needed to make IVM more consistent and effective so it can become a routine fertility option for a broader population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信